YahooSeptember 28, 2026 at 5:17 AM NY29 Days Ago
bioAffinity Technologies Builds Momentum for Non-Invasive Lung Cancer Detection
bioAffinity Technologies (NASDAQ:BIAF) is continuing to build momentum behind its non-invasive lung cancer diagnostic, CyPath Lung, with new clinical evidence and an expanding route into the US federal healthcare market. The company is presenting real-world clinical cases and new research focused on veteran and military populations at the 2026 NAVREF Annual Conference, highlighting the potential role of CyPath Lung in helping physicians make more informed diagnostic decisions.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
